Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an analysis of PFE stock now.

Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.